On February 22nd, 2021, the Food and Drug Administration (FDA) approved Libtayo (cemiplimab-rwlc) for the treatment of advanced non-small cell lung cancer (NSCLC) with no changes in EGFR, ALK, or ROS1 but with high PD-L1. The FDA based their [...]